Abstract
The therapeutic landscape for metastatic renal cell carcinoma (mRCC) has been revolutionized by recent randomized controlled trials of recent US Food and Drug Administration approved immune checkpoint inhibitors (ICI) combinations that demonstrated improved patient outcomes, but the optimal treatment sequence in patients with mRCC remains unclear. To inform policy makers about the value of these treatments, we developed a Markov model to compare the cost effectiveness of different strategies for sequencing novel agents for the treatment of mRCC.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
